Predict your next investment

HEALTHCARE | Drug Development
precision-biologics.com

See what CB Insights has to offer

Founded Year

2012

Stage

Corporate Majority | Acquired

Total Raised

$4.09M

About Precision Biologics

Precision Biologics is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way we detect and treat cancer.

Precision Biologics Headquarter Location

5910 North Central Expressway Suite 1300

Dallas, Texas, 75206,

United States

214-696-4999

Latest Precision Biologics News

Ambrx与领先的医疗保健投资者完成2亿美元的交叉融资,以推进其精密生物制品的临床和临床前管道

Nov 11, 2020

Ambrx与领先的医疗保健投资者完成2亿美元的交叉融资,以推进其精密生物制品的临床和临床前管道 本文共1269个字,阅读需4分钟 Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed US$200 million crossover financing round.New investors include Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management. BofA Securities acted as the sole placement agent for the offering. "This financing represents our most significant capital raise to date and includes several leading global and US based healthcare funds. Since mid-2018, our new management team, set on a new long term vision, has committed to building company fundamentals and transforming Ambrx from a technology developer to a full-fledged biopharmaceutical company," said Dr. Feng Tian, CEO and Chairman of Ambrx. "The conclusion of this financing and the strong data emerging from our ongoing clinical programs, as well as our deep preclinical pipeline of proprietary drug candidates, positions the company for rapid growth. "Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long acting therapeutic peptides for metabolic and cardiovascular disease.The company's innovation engine continues to expand the clinical and preclinical pipeline by discovering new and valuable programs that take full advantage of the Ambrx technologies. These novel programs have the potential to address a wide range of diseases with new or improved mechanisms of action, providing the company with a rich set of programs to develop internally or in partnership with leading pharmaceutical companies.About AmbrxAmbrx Inc. is a clinical stage biopharmaceutical company using an expanded geneticcode to create Precision Biologics, this includes next generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as novel cytokines to modulate the immune system and long acting therapeutic peptides for metabolic and cardiovascular disease, all designed to have improved pharmacologic properties and novel biological activity. Leveraging the Ambrx proprietary technology platforms, Ambrx has collaborations with Bristol-Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and ZMC, with drug products generated using Ambrx technology in different stages of clinical trials. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use in multiple therapeutic areas. For additional information, visit www.ambrx.com.Contact:Amy Conrad858-366-3243amy@juniper-point.commultimedia:http://www.prnewswire.com/news-releases/ambrx-closes-200-million-in-crossover-financing-with-leading-healthcare-investors-to-advance-its-clinical-and-preclinical-pipeline-of-precision-biologics-301168759.html Ambrx公司是一家临床阶段的生物制药公司,专注于利用扩大的遗传密码开发精密生物制品,今天宣布成功完成了一轮获得超额认购的2亿美元交叉融资。新的投资者包括富达管理研究公司,贝莱德管理的基金和账户,Cormorant资产管理公司,HBM Healthcare Investments,Invus,Adage Capital Partners和Suvretta Capital Management。美银证券担任是次发售的独家配售代理。Ambrx首席执行官兼董事长冯田博士表示:“此次融资是我们迄今为止最重要的一次融资,包括数家全球和美国领先的医疗保健基金。自2018年年中以来,我们的新管理团队基于新的长期愿景,致力于打造公司基础,并将Ambrx从一家技术开发商转变为一家成熟的生物制药公司。”这笔融资的结束,我们正在进行的临床项目中出现的强大数据,以及我们深入的临床前专利候选药物管道,为公司的快速增长奠定了基础。“Ambrx技术使用一种扩展的遗传密码将合成氨基酸并入蛋白质中,所有这些都在一个活细胞内完成。这些合成氨基酸使精确生物制剂的产生成为一种激动人心的新型疗法,具有广泛的应用和潜力。这包括下一代抗体药物结合物(ADCs),双特异性,针对癌症的靶向免疫肿瘤疗法,调节免疫系统的智能细胞因子,以及针对代谢和心血管疾病的长效治疗肽。该公司的创新引擎继续通过发现充分利用Ambrx技术的新的和有价值的项目来扩大临床和临床前管道。这些新颖的方案有潜力以新的或改进的作用机制来解决广泛的疾病,为公司提供了一套丰富的方案,可在内部或与领先的制药公司合作开发。关于AmbrxAmbrx Inc.是一家临床阶段生物制药公司,使用扩展的基因创造精确生物制剂的代码,这包括下一代抗体药物缀合物,双特异性,针对癌症的靶向免疫肿瘤疗法,以及调节免疫系统的新型细胞因子和针对代谢和心血管疾病的长效治疗肽,所有这些都被设计为具有改进的药理特性和新颖的生物活性。利用Ambrx专有技术平台,Ambrx与百时美施贵宝,Astellas,BeiGene,Sino Biopharma,Elanco和ZMC合作,在临床试验的不同阶段使用Ambrx技术生产药物产品。Ambrx公司正在推进一系列针对多个治疗领域的有效性,安全性和易用性进行优化的临床和临床前项目。欲了解更多信息,请访问www.ambrx.com。联系人:艾米·康拉德858-366-3243电子邮件:amy@juniper-point.com多媒体:http://www.prnewswire.com/news-releases/ambrx-closes-200-million-in-crossover-financing-with-leading-healthcare-investors-to-advance-its-clinical-and-preclinical-pipeline-of-precision-biologics-301168759.html 以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

Nov 10, 2020
Ambrx Lands $200M

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Precision Biologics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Precision Biologics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Precision Biologics Patents

Precision Biologics has filed 30 patents.

The 3 most popular patent topics include:

  • Immunology
  • Monoclonal antibodies
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/27/2019

8/3/2021

Clusters of differentiation, Glycoproteins, Transcription factors, Proteins, Immunology

Grant

Application Date

11/27/2019

Grant Date

8/3/2021

Title

Related Topics

Clusters of differentiation, Glycoproteins, Transcription factors, Proteins, Immunology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.